Metromic/Metromic Forte Drug Interactions

Metronidazole, after being absorbed can cause reaction when used along with the following drugs: Alcohol: alcohol intolerance (disulfiram-like reaction).
Amiodarone: increase in risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Astemizole and terfenadine: metronidazole inhibits the metabolism of these drugs and increases their plasma concentrations.
Carbamazepine: increase in blood concentration of carbamazepine.
Cimetidine: increase in blood level of metronidazole and the risk of neurologic side effects.
Cyclosporine: increase in cyclosporine toxicity.
Disulfiram: central nervous system related effects (e.g. psychotic reactions).
Fluorouracil: increase in blood levels of fluorouracil and toxicity.
Lithium: increase in lithium toxicity.
Oral anticoagulants: increase in anticoagulant effect (increase in bleeding risk).
Phenytoin: increase in blood levels of phenytoin, decrease in blood levels of metronidazole.
Phenobarbital: decrease in blood levels of metronidazole.
Interference with blood levels of liver enzymes, glucose (hexokinase method), theophylline and procainamide have been observed during the treatment with metronidazole.
Due to Miconazole nitrate absorption, the following interactions can be seen if used concomitantly with the drugs as follows: Acenocoumarol, anisindione, dicumarol, phenindione, phenprocoumon, warfarin: increase in bleeding risk.
Astemizole, cisapride and terfenadine: miconazole inhibits the metabolism of these drugs and increases their plasma concentrations.
Carbamazepine: reduction in carbamazepine metabolism.
Cyclosporine: increase risk of cyclosporine toxicity (renal dysfunction, cholestasis, paresthesias).
Fentanyl: increase or prolonged effects of opioid (CNS depression, respiratory depression).
Glimepiride: increase of hypoglycemic action.
Oxybutynin: increase in plasma concentration or exposure to oxybutynin, (dry mouth, constipation, headache).
Oxycodone: increase in oxycodone plasma concentration and reduction in clearance.
Phenytoin and phosphenytoin: increase risk of phenytoin toxicity (ataxia, hyperreflexia, nystagmus, tremor).
Pimozide: increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Trimetrexate: increase in trimetrexate toxicity (bone marrow suppression, renal and hepatic dysfunction and gastrointestinal ulceration).
Additional information on special populations: No interaction study has been conducted on special populations.
Paediatric population: No interaction study has been conducted in children.